Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

RF pain device developer Relievant completes $30mm Series D financing

Executive Summary

New Enterprise Associates has led a $30mm Series D round for Relievant Medsystems Inc. (radiofrequency nerve ablation devices). Returning shareholders Canaan Partners, Emergent Medical Partners, Morgenthaler Ventures, and Onset Ventures also joined. The funding will support Relievant’s recently initiated surgical multi-center assessment of RF ablation for the treatment of vertebrogenic back pain (SMART) trial, which will evaluate the Intracept system in chronic axial low back pain. The minimally invasive probe delivers radiofrequency ablation to prevent pain signals from being transmitted by the basivertebral nerve.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Radiofrequency Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies